Yes to AIDS drug

October 1991
New Scientist;10/19/91, Vol. 132 Issue 1791, p15
Reports on the U.S. and Canadian health authorities' joint approval of a second AIDS drug called didanosine of ddl developed by Bristol-Myers Squibb Co. Evidence that ddl helps maintain higher levels of certain white blood cells which HIV attacks; Estimated annual cost of ddl treatment per patient; Comparison with AZT.


Related Articles

  • AIDS: The New Drug War. Smith, Liz // Fortune;4/27/1998, Vol. 137 Issue 8, p60 

    Focuses on the battle between Glaxo Wellcome and Britol-Myers Squibbs over market share for their drugs used to combat AIDS. Glaxo's nucleoside reverse transcriptase inhibitor known as AZT; Bristol-Meyers' introduction of Zerit; Sales figures; The success of Bristol in marketing its drug.

  • Welcoming Atripla. McManus, Michael // Advocate;8/29/2006, Issue 969, p47 

    The article reports on the approval of the antiretroviral HIV/AIDS drug Atripla from Bristol-Mayers Squibb by the U.S. Food and Drug Administration. When the first antiretroviral HIV/AIDS drugs were approved by the Food and Drug Administration 10 years ago, many patients were taking more than 20...

  • Single daily pill for HIV in development. Roehr, Bob // Bay Area Reporter;12/23/2004, Vol. 34 Issue 52, p17 

    Reports that a single pill once a day to treat HIV is the goal set by Bristol-Myers Squibb and Gilead Sciences which have agreed to collaborate. Bristol-Myers Squibb as producer of Sustiva, a non-nucleoside reverse transcriptase inhibitor; Gilead Sciences as producer of Viread and Emtriva, two...

  • BMS Stands Down.  // Multinational Monitor;Jan/Feb2004, Vol. 25 Issue 1/2, p4 

    Reports on the decision of Bristol-Myers Squibb company to abandon a lawsuit filed by AIDS activists in Thailand against its patent on an AIDS drug in 2004. Argument raised by the activists; Reason behind the company's move.

  • HIV market: collaborative combinations.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p25 

    The article presents analyzes the competition between several pharmaceutical companies that develop HIV drugs. The companies Tibotec and Gilead Inc., that are launching new HIV drugs, TMC278 and elvitegravir respectively, are expected to compete with Bristol-Myers Squibb Co.'s Sustiva, and Merck...

  • New management.  // Crain's New York Business;11/16/98, Vol. 14 Issue 46, p62 

    Focuses on changes in the management structure of Bristol-Myers Squibb Co.

  • Consumers targeted by Capoten promo.  // Drug Topics;9/5/94, Vol. 138 Issue 17, p8 

    Reports that Bristol-Myers Squibb has enlisted chain pharmacies in its first direct-to-consumer marketing campaign.

  • A hard one to swallow.  // Drug Topics;11/7/94, Vol. 138 Issue 21, p7 

    Reports that Bristol-Myers Squibb is withdrawing Questran tablets from the market after a patient choked on the large tablet.

  • Labelers glide along smoothly for Bristol-Myers' ban. Hartman, Lauren R. // Packaging Digest;Sep97, Vol. 34 Issue 10, p84 

    Focuses on the packaging of the Ban, clear soft solid antiperspirant/deodorant, by Bristol-Myers Squibb. Comments from Ken Laing, senior project engineering manager at Bristol-Myers; What discovery did Laing make; Description of the features of this product.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics